Table 1.
Treatment | Day 64 of life | Day 225 of life | ||
---|---|---|---|---|
Vehicle | sRAGE | Vehicle | sRAGE | |
CML (nmol/mmol Lys) | 32.2 (3.5) | 31.1 (3.7) | 76.5 (10.6) | 71.1 (12.4)* |
CEL (nmol/mmol Lys) | 13.5 (4.0) | 16.2 (8.0) | 15.4 (3.8) | 12.3 (4.2)* |
MG-H1 (nmol/mmol Lys) | 229.3 (45.1) | 260.1 (56.4) | 267.7 (39.5) | 247.0 (54.6)* |
MGO (nmol/L) | 499.5 (78.8) | 436.4 (142.9) | 643.7 (280.2) | 556.1 (246.4) |
GO (nmol/L) | 848.4 (301.8) | 958.3 (316.0) | 1,083.0 (505.2) | 1,004.0 (518.5) |
3-DG (nmol/L) | 987.3 (254.7) | 1,163.0 (401.0) | 2,547.0 (476.0) | 2,227.0 (483.0) |
S100A8 (ng/mL) | 0.5 (0.1) | 7.1 (23.0) | 5.3 (13.1) | 5.0 (26.0) |
S100A9 (ng/mL) | 166.8 (131.8) | 301.3 (303.0) | 74.9 (144.3) | 100.5 (81.8) |
S100B (ng/mL) | 1,081.0 (812.9) | 882.5 (512.7) | 1,052.0 (528.8) | 1,077.0 (545.6) |
HMGB1 (ng/mL) | 11.9 (7.5) | 15.8 (8.2) | 7.1 (3.7) | 5.7 (5.0) |
Data shown as median (IQR), with analysis with two-tailed Mann-Whitney U test. n = 12–15/group. 3-DG, 3-deoxyglucosone; GO, glyoxal; Lys, lysine; MGO, methylglyoxal.
P < 0.05 vs. vehicle at same time point.